Human Thrombomodulin (BDCA-3) Recombinant Protein, PeproTech

The University of Virginia awarded contract A207_PO-0477656 to Life Technologies Corporation on September 5, 2026, for the procurement of specialized biological materials. The single line item contract encompasses the delivery of Human Thrombomodulin (BDCA-3) Recombinant Protein manufactured by PeproTech, with a quantity of one unit ordered at a unit price of $220.50. The total contract amount is $220.00, with delivery designated to Shilpa R Kumbhar at the University of Virginia location in Virginia.

This procurement represents a straightforward purchase order for research-grade biological reagents commonly utilized in laboratory and academic research settings. The Human Thrombomodulin recombinant protein product is a specialized scientific material with applications in immunology and cell biology research. While the contract documentation does not specify an explicit performance period or extended delivery timeline, the award date of September 5, 2026, marks the contract initiation. The modest contract value and single-unit procurement structure indicate this represents a routine materials supply transaction rather than a comprehensive service engagement.